🗂️
Archived grant — no longer open
This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.
grant
Revealing the cis-Regulatory Function of IMiDs in Multiple Myeloma”.
Organization EMORY UNIVERSITYLocation ATLANTA, UNITED STATESPosted 7 Dec 2022Deadline 30 Nov 2025 ⚠️
NIHUS FederalResearch GrantFY2025AblationAccelerationAffectAnti-OncogenesAntibodiesAntioncogenesBasal Transcription FactorBasal transcription factor genesBindingBinding ProteinsBinding SitesBlood Plasma CellCCND1 ProteinCRISPR activationCRISPR activatorCRISPR based activationCRISPR gene activationCRISPR interferenceCRISPR transcription activationCRISPR transcriptional activationCRISPR-Cas-9-mediated gene activationCRISPR-based gene activationCRISPR-dCAS9 ActivatorCRISPR-dCas9-mediated repressionCRISPR-mediated transcriptional activationCRISPR/CAS9 activationCRISPR/CAS9 gene activationCRISPR/dCas9 activationCRISPR/dCas9 interferenceCRISPR/dCas9-based transcriptional activationCRISPR/dCas9-mediated transcriptional inhibitionCRISPRaCRISPRiCancer CauseCancer EtiologyCancer GenesCancer Suppressor GenesCancer-Promoting GeneCancersCell BodyCellsCellular ExpansionCellular GrowthCellular OncogeneCessation of lifeChIP SequencingChIP-seqChIPseqChromatinChromosomesClustered Regularly Interspaced Short Palindromic Repeats interferenceCombining SiteCyclin D1DNA AlterationDNA Sequence AlterationDataDeathDefectDependenceDiagnosisDiseaseDisorderDrug resistanceDrugsEctopic ExpressionElementsEmerogenesEnhancersEpigeneticEpigenetic ChangeEpigenetic MechanismEpigenetic ProcessEventG1/S-Specific Cyclin D1Gene Down-RegulationGene ExpressionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenesGeneticGenetic AlterationGenomeGenomicsGoalsGrowthHeavy-Chain ImmunoglobulinsImidesImmune mediated therapyImmunologically Directed TherapyImmunomodulationImmunotherapyIn SituIndividualInfectionLigand Binding ProteinLigand Binding Protein GeneLight-Chain ImmunoglobulinsLocationLymphatic cellLymphocyteLymphocyticMalignant NeoplasmsMalignant TumorMeasuresMediatingMedicationModalityMolecularMolecular InteractionMolecular TargetMultiple MyelomaNGS MethodNGS systemNewly DiagnosedOnco-Suppressor GenesOncogenesOncogenes-Tumor SuppressorsOutcomePRAD1 ProteinPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPharmaceutical PreparationsPhenotypePlasma CellsPlasma-Cell MyelomaPlasmacytesPositionPositioning AttributeProliferatingProteasome InhibitorProtein BindingProto-Oncogene Proteins c-bcl-1Proto-OncogenesRNA SeqRNA sequencingRNAseqReactive SiteRecessive OncogenesRefractoryRegulatory ElementResearchResearch SpecimenResistanceResistance developmentResistant developmentRoleRunningScientistSedalisSequence AlterationSpecimenTestingThalidomideTherapeuticTherapeutic EffectTissue GrowthTranscription Factor Proto-OncogeneTranscription RepressionTranscription factor genesTransforming GenesTranslatingTrisomyTumor Suppressing GenesTumor Suppressor GenesValidationWorkactivating CRISPR technologyanalogbcl-1 Proto-Oncogene Productsbcl-1 Proto-Oncogene Proteinsbcl1 Proto-Oncogene Proteinsbound proteinc-ONCc-bcl-1 Proteinscareercell growthchromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingcyclin Ddeveloping resistancedrug resistantdrug sensitivitydrug-sensitivedrug/agentepigeneticallyepigenomeexperimentexperimental researchexperimental studyexperimentsexpression subtypesgene repressiongenomic alterationgenomic datagenomic datasethistone H3 methyltransferasehistone methylasehistone methyltransferasehistone modificationimmune modulationimmune regulationimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune-based therapiesimmune-based treatmentsimmuno therapyimmunologic reactivity controlimmunomodulatoryimmunoregulationimmunoregulatoryimprovedin vivo Modelinnovateinnovationinnovativeinsightlymph cellmalignancymolecular sub-typesmolecular subsetsmolecular subtypesmortalitymyelomamyelomatosisneoplasm/cancernew approachesnext gen sequencingnext generation sequencingnextgen sequencingnovel approachesnovel strategiesnovel strategyoncosuppressor geneontogenyoverexpressoverexpressionpatient oriented outcomesplasmocyteprognosticprogramspromoterpromotorprotooncogenerepressing CRISPR-dCas9 systemresistance to Drugresistantresistant to Drugresponseresponse to therapyresponse to treatmentsocial rolestructural mutationstructural variantstructural variationtherapeutic responsetherapeutic targettherapy responsetranscription factortranscriptome sequencingtranscriptomic sequencingtreatment responsetreatment responsivenessvalidations
Applications closed.
Description preview
Project Summary
Multiple myeloma is a cancer of plasma cells resulting in over 12,000 U.S. deaths each year. Genetic alterations
in myeloma include trisomy of most odd-numbered chromosomes, translocations that result in ectopic expression
of oncogenes as well as structural variants and mutations in oncogenes and tumor suppressor genes. These…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click